Targeting angiogenesis in melanoma: prospects for the future

Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study

(2017) J. P. Fruehauf et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I dose finding and biomarker study of TKI258 (dovitinib lactate) in patients with advanced melanoma

(2017) K. B. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736)

(2017) B. I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08

(2017) N. Wolmark et al.   JOURNAL OF CLINICAL ONCOLOGY

Interferon-α as angiogenesis inhibitor: Learning from tumor models

(2010) Stefano Indraccolo   AUTOIMMUNITY

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

(2010) Jennifer L. Spratlin et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

(2009) N Murukesh et al.   BRITISH JOURNAL OF CANCER

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

(2009) R. K. Amaravadi et al.   CLINICAL CANCER RESEARCH

23LBA BEAM: A randomized phase II study evaluating the activity of BEvacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated Advanced Melanoma

(2009) S.J. O'Day et al.   EJC SUPPLEMENTS

9305 Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers

(2009) L. Decoster et al.   EJC SUPPLEMENTS

Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: Correlation with clinical parameters and outcome

(2009) Roger Mouawad et al.   EUROPEAN JOURNAL OF CANCER

Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies

(2009) Bristi Basu et al.   Expert Review of Anticancer Therapy

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

(2009) Axel Hauschild et al.   JOURNAL OF CLINICAL ONCOLOGY

Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer

(2009) Roopali Roy et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma

(2009) Lavanya H Palavalli et al.   NATURE GENETICS

Angiogenesis in pre-malignant conditions

(2008) S R Menakuru et al.   BRITISH JOURNAL OF CANCER

Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma

(2008) Domingo G. Perez et al.   CANCER

Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group

(2008) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694

(2008) Ahmad A. Tarhini et al.   JOURNAL OF CLINICAL ONCOLOGY

Preliminary Results of the Combination of Bevacizumab and Weekly Paclitaxel in Advanced Melanoma

(2008) M. González-Cao et al.   ONCOLOGY